Last updated: February 19, 2026
This report analyzes the suppliers for the pharmaceutical drug ROBINUL (glycopyrrolate). Key suppliers identified include active pharmaceutical ingredient (API) manufacturers, finished dosage form (FDF) manufacturers, and packaging material providers. The analysis focuses on identifying key players, their geographic locations, and potential supply chain vulnerabilities.
What is ROBINUL and its Active Pharmaceutical Ingredient (API)?
ROBINUL is a brand name for glycopyrrolate, an anticholinergic medication used to reduce secretions, slow the heart rate, and reduce gastrointestinal (GI) spasms. It is prescribed to treat conditions such as peptic ulcers, irritable bowel syndrome, and as a preoperative medication to reduce secretions [1]. The active pharmaceutical ingredient is glycopyrrolate.
Who Manufactures the Glycopyrrolate API?
The manufacturing of the glycopyrrolate API is concentrated among a limited number of global suppliers. These entities are crucial to the ROBINUL supply chain, as their production capacity and quality control directly impact the availability and purity of the drug.
Which Companies Produce the Finished Dosage Form (FDF) of ROBINUL?
The formulation and packaging of glycopyrrolate into its final dosage forms (e.g., tablets, injectable solutions) are carried out by FDF manufacturers. These companies convert the API into a ready-to-administer product.
Who Supplies Packaging Materials for ROBINUL?
Reliable and compliant packaging is essential for drug stability, safety, and regulatory adherence. This includes primary packaging (in direct contact with the drug) and secondary packaging.
-
Primary Packaging Suppliers (e.g., Blister Packs, Vials, Ampoules):
- Gerresheimer AG: A leading global supplier of specialty glass and plastic products for the pharmaceutical industry, including vials and ampoules.
- Owens-Illinois, Inc.: A major global manufacturer of glass containers, including pharmaceutical vials.
- Amcor plc: A global leader in developing and producing responsible packaging for food, beverage, pharmaceutical, medical, home and personal care, and other products. They supply blister films and other plastic components.
- Schott AG: A German manufacturer of glass and glass-ceramic products, including pharmaceutical packaging like vials and ampoules.
-
Secondary Packaging Suppliers (e.g., Cartons, Labels):
- Graphic Packaging International, LLC: A leading provider of paper-based packaging solutions, including folding cartons for pharmaceuticals.
- CCL Industries Inc.: A global producer of specialty labels and packaging, including pharmaceutical labels and shrink sleeves.
- WestRock Company: A provider of paper and packaging solutions, producing folding cartons and other secondary packaging.
What are the Regulatory Considerations for ROBINUL Suppliers?
All suppliers in the ROBINUL supply chain must adhere to stringent regulatory requirements to ensure product quality, safety, and efficacy.
- Good Manufacturing Practices (GMP): All API and FDF manufacturers must comply with current GMP regulations as established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities [2]. This includes strict quality control, process validation, and documentation.
- Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality controls of the API. FDF manufacturers can reference these DMFs in their drug applications [3].
- Pharmacopeial Standards: Glycopyrrolate API and finished products must meet the standards outlined in official pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.) [4].
- ICH Guidelines: Compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines is crucial, particularly for quality, safety, and efficacy aspects.
What are the Potential Supply Chain Risks?
The ROBINUL supply chain, like many in the pharmaceutical industry, faces several potential risks that could impact product availability.
- API Manufacturing Concentration: Reliance on a limited number of API manufacturers, particularly those concentrated in specific geographic regions (e.g., India, China), creates vulnerability to geopolitical events, natural disasters, or regulatory actions affecting those regions.
- Quality Control Failures: Any lapse in quality control by API or FDF manufacturers can lead to batch rejections, recalls, and significant supply disruptions.
- Regulatory Changes: Unexpected changes in GMP regulations or import/export policies in key manufacturing countries can impact production and distribution.
- Geopolitical Instability: Conflicts, trade disputes, or political unrest in regions where key suppliers are located can disrupt raw material sourcing and finished product manufacturing.
- Raw Material Shortages: The synthesis of glycopyrrolate requires specific starting materials and reagents. Shortages of these precursors can halt API production.
- Logistics and Transportation: Global shipping disruptions, port congestion, or increased freight costs can affect the timely delivery of APIs and finished products.
- Single-Source Dependency: If a critical component or the API itself is sourced from a single supplier, any disruption to that supplier's operations poses a significant risk.
- Intellectual Property Issues: While ROBINUL is an established drug, patent expiry and the emergence of generic competition can lead to price pressures and shifts in market dynamics, potentially impacting supplier viability.
Key Takeaways
The supply chain for ROBINUL is complex, involving specialized API manufacturers, branded FDF producers like Premier Pharmaceuticals, and a network of packaging material suppliers. Geographic concentration of API manufacturing, primarily in India and China, presents a notable risk. Compliance with stringent GMP regulations and pharmacopoeial standards is mandatory for all participants. Potential supply chain disruptions stem from quality control issues, geopolitical events, raw material availability, and logistical challenges.
Frequently Asked Questions
- What are the primary regions for glycopyrrolate API manufacturing?
The primary regions for glycopyrrolate API manufacturing are India and China, with some specialized production in Europe and North America.
- Who holds the New Drug Application (NDA) for the ROBINUL brand in the US?
Premier Pharmaceuticals holds the New Drug Application (NDA) for the ROBINUL brand in the United States.
- What are the main dosage forms of glycopyrrolate?
The main dosage forms of glycopyrrolate are oral tablets (typically 1 mg and 2 mg) and injectable solutions.
- Are there significant single-source dependencies within the ROBINUL supply chain?
While specific supplier relationships can change, the concentration of API manufacturing in a few key global regions and for certain specialized intermediates can create de facto single-source dependencies.
- What regulatory standards must suppliers of ROBINUL meet?
Suppliers must meet Good Manufacturing Practices (GMP) as defined by regulatory bodies like the FDA and EMA, comply with pharmacopoeial standards (USP, Ph. Eur.), and adhere to ICH guidelines.
Citations
[1] FDA. (n.d.). Prescribing Information: ROBINUL. U.S. Food and Drug Administration.
[2] U.S. Food and Drug Administration. (2023, April 19). Current Good Manufacturing Practice (CGMP) in Manufacturing, Processing, Packing, or Holding of Drugs; General.
[3] U.S. Food and Drug Administration. (2023, July 12). Drug Master Files (DMFs).
[4] United States Pharmacopeia. (n.d.). USP-NF Online.
